AAIC 2020 updates: COVID-19 and Alzheimer's, measuring dementia risk in youth and more
Click Here to Manage Email Alerts
Healio Psychiatry has compiled a list of five major stories from the Alzheimer’s Association International Conference 2020.
Insights on COVID-19’s effects on patients with Alzheimer’s and dementia, research on the role of flu and pneumonia vaccines in reducing Alzheimer’s risk and data on the potential of detecting Alzheimer’s risk in youth were among the presentation topics at the virtual meeting.
Which story resonated with you most? Leave a comment or write to us on Twitter @HealioPsych.
COVID-19 may disproportionately affect patients with Alzheimer’s disease, dementia
The COVID-19 pandemic has impacted research, outcomes, long-term care and disparities related to Alzheimer’s disease and other dementias, according to Gregory Jicha, MD, PhD, chair of the Alzheimer’s Association Clinical Trials Advancement and Methods professional interest area, and other presenters. Read more.
Flu, pneumonia vaccinations may reduce risk for Alzheimer’s disease
Flu and pneumonia vaccines appeared linked to reduced risk for Alzheimer’s disease, according to Albert Amran, a fourth-year medical student at McGovern Medical School at the University of Texas Health Science Center at Houston, and other presenters. Read more.
Dementia risk likely measurable among adolescents, young adults
Alzheimer’s dementia risk factors may be measurable among adolescents and young adults, according to Kristen George, PhD, MPH, of the University of California, Davis. Read more.
Blood tests may soon accurately detect Alzheimer’s disease
Recent advances in blood tests suggest future tests may be able to detect Alzheimer’s disease, according to Sebastian Palmqvist, MD, PhD, of Lund University in Sweden, and other presenters. Read more.
Hallucinations, distorted senses common symptoms of dementia-related psychosis
Individuals with dementia-related psychosis commonly experience visual hallucinations, auditory hallucinations and distortion of senses, according to Teresa Brandt, PhD, executive director of regulatory affairs at ACADIA Pharmaceuticals, and colleagues. Read more.